Predicting which potential medicines could be harmful to major organ systems is a major challenge during drug development. The TransBioLine project aims to develop biological markers (biomarkers) that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system. The biomarkers, which the project hopes to get through regulatory qualification, include indicators of tissue damage, biomarkers to aid patient stratification, and standardised tests for the detection of the biomarkers. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, and it will be able to provide the scientific community, industry and patients with detailed data and information across a large spectrum of advanced safety biomarkers. Ultimately, the new markers will not only improve the safety of new drugs, but will contribute to the better diagnosis and management of diseases.
TransBioLine
Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
FACTS & FIGURES
| Start Date |
|
| End Date |
|
| Call |
IMI2 - Call 13
|
| Grant agreement number |
821283
|
Type of Action:
RIA (Research and Innovation Action)
| Contributions | € |
|---|---|
| IMI Funding |
13 999 998
|
| EFPIA in kind |
13 906 494
|
| Total Cost |
27 906 492
|
Summary
Participants Show participants on map
EFPIA companies
- Eli Lilly and Company Limited, Basingstoke, United Kingdom
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
- Novartis Pharma AG, Basel, Switzerland
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
- Assistance Publique Hopitaux De Paris, Paris, France
- Charite - Universitaetsmedizin Berlin, Berlin, Germany
- Landspitali University Hospital, Reykjavik, Iceland
- Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
- Servicio Andaluz De Salud, Sevilla, Spain
- The University Of Liverpool, Liverpool, United Kingdom
- The University Of Nottingham, Nottingham, United Kingdom
- Universidad De Malaga, Malaga, Spain
- Universidad De Salamanca, Salamanca, Spain
- Universitat Zurich, Zürich, Switzerland
- Universiteit Leiden, Leiden, Netherlands
- University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Abx Cro Advanced Pharmaceutical Services Forschungsgesellschaft Mbh, Oberwil, Switzerland
- Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
- Metaheps GMBH, Munich, Germany
- Mlm Medical Labs GMBH, Moenchengladbach, Germany
- Signatope GMBH, Reutlingen, Germany
- Synapse Research Management Partners SL, Barcelona, Spain
- Tamirna GMBH, Vienna, Austria
Patient organisations
- Fundacio Privada Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
| Participants | |
|---|---|
| Name | IMI funding in € |
| Abx Cro Advanced Pharmaceutical Services Forschungsgesellschaft Mbh | 1 294 360 |
| Assistance Publique Hopitaux De Paris | 81 400 |
| Charite - Universitaetsmedizin Berlin | 1 386 194 |
| Fundacio Privada Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau | 182 600 |
| Information Technology For Translational Medicine (Ittm) SA | 624 125 |
| Landspitali University Hospital | 87 325 |
| Ludwig-Maximilians-Universitaet Muenchen | 443 450 |
| Metaheps GMBH | 284 000 |
| Mlm Medical Labs GMBH | 604 800 |
| Servicio Andaluz De Salud | 188 946 |
| Signatope GMBH | 1 990 000 |
| Synapse Research Management Partners SL | 900 000 |
| Tamirna GMBH | 1 231 000 |
| The University Of Liverpool | 940 250 |
| The University Of Nottingham | 832 700 |
| Universidad De Malaga | 246 452 |
| Universidad De Salamanca | 69 500 |
| Universitat Zurich | 2 424 271 |
| Universiteit Leiden | 79 150 |
| University Of Newcastle Upon Tyne | 109 475 |
| Total Cost | 13 999 998 |
CONTACT
Project coordinator
Michael Merz
UNIVERSITAT ZURICH
michael.merz[at]usz.ch
Michael Merz
UNIVERSITAT ZURICH
michael.merz[at]usz.ch
LINKS AND DOCUMENTS
Project website
transbioline.com
Twitter
@IMITransBioLine